Galectin Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.16 | -$0.16 | -$0.16 |
| Q2 2024 | 1 | -$0.20 | -$0.20 | -$0.20 |
| Q3 2024 | 1 | -$0.16 | -$0.16 | -$0.16 |
| Q1 2025 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q2 2025 | 1 | -$0.26 | -$0.26 | -$0.26 |
| Q3 2025 | 1 | -$0.63 | -$0.63 | -$0.63 |
| Q4 2025 | 1 | -$0.53 | -$0.53 | -$0.53 |
Galectin Therapeutics Inc. Earnings Date And Information
Galectin Therapeutics Inc. last posted its earnings results on Tuesday, August 13th, 2024. The company reported $-0.2 earnings per share for the quarter, missing analysts' consensus estimates of $-0.16 by $0.04. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Galectin Therapeutics Inc. has generated $-1 earnings per share over the last year ($-0.74 diluted earnings per share) and currently has a price-to-earnings ratio of -3.72. Galectin Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based on prior year's report dates.
Galectin Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.18 | $0 | $0 | ||
| 08/13/2024 | Q2 2024 | -$0.16 | -$0.20 | -0.04 | $0 | $0 |
| 05/15/2024 | Q1 2024 | -$0.16 | -$0.19 | -0.03 | $0 | |
| 03/29/2024 | Q4 2023 | -$0.16 | -$0.16 | 0 | $80,000 | |
| 11/13/2023 | Q3 2023 | -$0.16 | -$0.17 | -0.01 | $0 | |
| 08/14/2023 | Q2 2023 | -$0.21 | -$0.15 | 0.06 | $0 | |
| 05/15/2023 | Q1 2023 | -$0.21 | -$0.21 | 0 | $0 | |
| 03/30/2023 | Q4 2022 | -$0.17 | -$0.51 | -0.34 | $0 | |
| 11/14/2022 | Q3 2022 | -$0.20 | -$0.15 | 0.05 | $0 | |
| 08/15/2022 | Q2 2022 | -$0.19 | -$0.16 | 0.03 | $0 | |
| 05/16/2022 | Q1 2022 | -$0.10 | -$0.17 | -0.07 | $0 | |
| 03/31/2022 | Q4 2021 | -$0.19 | -$0.12 | 0.07 | $0 | |
| 11/15/2021 | Q3 2021 | -$0.18 | -$0.14 | 0.04 | $0 | |
| 08/16/2021 | Q2 2021 | -$0.18 | -$0.14 | 0.04 | $0 | |
| 05/17/2021 | Q1 2021 | -$0.17 | -$0.11 | 0.06 | $0 | |
| 03/31/2021 | Q4 2020 | -$0.16 | -$0.14 | 0.02 | $0 | |
| 11/09/2020 | Q3 2020 | -$0.14 | -$0.10 | 0.04 | $0 | |
| 08/10/2020 | Q2 2020 | -$0.09 | -$0.11 | -0.02 | $0 | |
| 05/11/2020 | Q1 2020 | -$0.08 | -$0.06 | 0.02 | $0 | |
| 03/16/2020 | Q4 2019 | -$0.06 | -$0.09 | -0.03 | $0 |
Galectin Therapeutics Inc. Earnings: Frequently Asked Questions
-
When is Galectin Therapeutics Inc.'s earnings date?
Galectin Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based off last year's report dates.
-
How can I listen to Galectin Therapeutics Inc.'s earnings conference call?
The conference call for Galectin Therapeutics Inc.'s latest earnings report can be listened to online.
-
How can I read Galectin Therapeutics Inc.'s conference call transcript?
The conference call transcript for Galectin Therapeutics Inc.'s latest earnings report can be read online.
-
How much profit does Galectin Therapeutics Inc. generate each year?
Galectin Therapeutics Inc. (:GALT) has a recorded net income of $0. Galectin Therapeutics Inc. has generated $-0.74 earnings per share over the last four quarters.
-
What is Galectin Therapeutics Inc.'s price-to-earnings ratio?
Galectin Therapeutics Inc. (:GALT) has a price-to-earnings ratio of -3.72 and price/earnings-to-growth ratio is 2.68.
